685 related articles for article (PubMed ID: 25555397)
1. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
2. New Features about Tau Function and Dysfunction.
Medina M; Hernández F; Avila J
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27104579
[TBL] [Abstract][Full Text] [Related]
3. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
4. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
5. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
6. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
7. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
8. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
9. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
10. An Overview on the Clinical Development of Tau-Based Therapeutics.
Medina M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
[TBL] [Abstract][Full Text] [Related]
11. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
13. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
14. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
15. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
16. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
Marcus JN; Schachter J
J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
[TBL] [Abstract][Full Text] [Related]
17. Tau in physiology and pathology.
Wang Y; Mandelkow E
Nat Rev Neurosci; 2016 Jan; 17(1):5-21. PubMed ID: 26631930
[TBL] [Abstract][Full Text] [Related]
18. Tau-based therapies in neurodegeneration: opportunities and challenges.
Li C; Götz J
Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
[TBL] [Abstract][Full Text] [Related]
19. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]